1	Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin
2	A.M. Turner ¹ , L. Li ¹ , I.R. Monk ¹ , J.Y.H. Lee ^{1,2} , D.J. Ingle ¹ , S. Duchene ¹ , N.L. Sherry ^{1,3,4} , T.P.
3	Stinear ¹ , J.C. Kwong ^{1,4} , C.L. Gorrie ^{1,3} *, B.P. Howden ^{1,3,4} *† and G.P. Carter ¹ *†
4	
5	¹ Department of Microbiology & Immunology, The Peter Doherty Institute for Infection and
6	Immunity, The University of Melbourne, Melbourne, VIC, Australia
7	² Department of Infectious Diseases, Monash Health, Clayton, VIC, Australia
8	³ Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and
9	Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and
10	Immunity, Melbourne, VIC, Australia
11	⁴ Department of Infectious Diseases, Austin Health, Melbourne, VIC, Australia
12	*These authors supervised this work equally.
13	+Corresponding authors: glen.carter@unimelb.edu.au, bhowden@unimelb.edu.au
13 14	⁺ Corresponding authors: <u>glen.carter@unimelb.edu.au</u> , <u>bhowden@unimelb.edu.au</u>
13 14 15	+Corresponding authors: <u>glen.carter@unimelb.edu.au</u> , <u>bhowden@unimelb.edu.au</u> Abstract
13 14 15 16	 +Corresponding authors: <u>glen.carter@unimelb.edu.au</u>, <u>bhowden@unimelb.edu.au</u> Abstract Bacterial pathogens such as vancomycin-resistant <i>Enterococcus faecium</i> (VREfm) that are
13 14 15 16 17	 +Corresponding authors: glen.carter@unimelb.edu.au, bhowden@unimelb.edu.au Abstract Bacterial pathogens such as vancomycin-resistant <i>Enterococcus faecium</i> (VREfm) that are resistant to almost all antibiotics are among the top global threats to human health.
13 14 15 16 17 18	 +Corresponding authors: glen.carter@unimelb.edu.au, bhowden@unimelb.edu.au Abstract Bacterial pathogens such as vancomycin-resistant <i>Enterococcus faecium</i> (VREfm) that are resistant to almost all antibiotics are among the top global threats to human health. Daptomycin is a new last-resort antibiotic for VREfm infections with a novel mode-of-action,
13 14 15 16 17 18 19	*Corresponding authors: glen.carter@unimelb.edu.au, bhowden@unimelb.edu.au Abstract Bacterial pathogens such as vancomycin-resistant <i>Enterococcus faecium</i> (VREfm) that are resistant to almost all antibiotics are among the top global threats to human health. Daptomycin is a new last-resort antibiotic for VREfm infections with a novel mode-of-action, but for which resistance has surprisingly and alarmingly been widely reported. The causes of
13 14 15 16 17 18 19 20	*Corresponding authors: glen.carter@unimelb.edu.au, bhowden@unimelb.edu.au Abstract Bacterial pathogens such as vancomycin-resistant <i>Enterococcus faecium</i> (VREfm) that are resistant to almost all antibiotics are among the top global threats to human health. Daptomycin is a new last-resort antibiotic for VREfm infections with a novel mode-of-action, but for which resistance has surprisingly and alarmingly been widely reported. The causes of such a rapid emergence of resistance to this novel antibiotic have been unclear. Here we show
13 14 15 16 17 18 19 20 21	*Corresponding authors: glen.carter@unimelb.edu.au, bhowden@unimelb.edu.au Abstract Bacterial pathogens such as vancomycin-resistant <i>Enterococcus faecium</i> (VREfm) that are resistant to almost all antibiotics are among the top global threats to human health. Daptomycin is a new last-resort antibiotic for VREfm infections with a novel mode-of-action, but for which resistance has surprisingly and alarmingly been widely reported. The causes of such a rapid emergence of resistance to this novel antibiotic have been unclear. Here we show that the use of rifaximin, an unrelated antibiotic used prophylactically to prevent hepatic
 13 14 15 16 17 18 19 20 21 22 	*Corresponding authors: glen.carter@unimelb.edu.au, bhowden@unimelb.edu.au Abstract Bacterial pathogens such as vancomycin-resistant <i>Enterococcus faecium</i> (VREfm) that are resistant to almost all antibiotics are among the top global threats to human health. Daptomycin is a new last-resort antibiotic for VREfm infections with a novel mode-of-action, but for which resistance has surprisingly and alarmingly been widely reported. The causes of such a rapid emergence of resistance to this novel antibiotic have been unclear. Here we show that the use of rifaximin, an unrelated antibiotic used prophylactically to prevent hepatic encephalopathy in liver disease patients, is causing resistance to this last-resort antibiotic in
 13 14 15 16 17 18 19 20 21 22 23 	*Corresponding authors: <u>glen.carter@unimelb.edu.au</u> , <u>bhowden@unimelb.edu.au</u> Abstract Bacterial pathogens such as vancomycin-resistant <i>Enterococcus faecium</i> (VREfm) that are resistant to almost all antibiotics are among the top global threats to human health. Daptomycin is a new last-resort antibiotic for VREfm infections with a novel mode-of-action, but for which resistance has surprisingly and alarmingly been widely reported. The causes of such a rapid emergence of resistance to this novel antibiotic have been unclear. Here we show that the use of rifaximin, an unrelated antibiotic used prophylactically to prevent hepatic encephalopathy in liver disease patients, is causing resistance to this last-resort antibiotic in VREfm. We show that mutations within the bacterial RNA polymerase complex confer cross-

spread globally across at least 5 continents and 20 countries, making this a major yet previously unrecognised mechanism of resistance. Until now, rifaximin has been considered 'low-risk' for development of antibiotic resistance. Our study shows this is not the case and that widespread rifaximin use may be compromising the clinical efficacy of daptomycin, one of the major last-resort interventions for multidrug resistant pathogens. These findings demonstrate that unanticipated antibiotic cross-resistance may potentially undermine global strategies designed to preserve the clinical use of last-resort antibiotics.

- 32
- 33 Main

34 Antimicrobial resistance (AMR) is one of the greatest public health threats that humanity 35 currently faces, with 1.27 million deaths being directly attributable to bacterial AMR in 2019¹. 36 The magnitude of this threat is therefore similar to that of malaria (558,000 global deaths in 2019², HIV (690,000 deaths in 2019)³, and diabetes mellitus (1.5 million deaths in 2019)⁴. 37 38 Infectious caused by multidrug (MDR) and extensively drug resistant (XDR) pathogens are of 39 particular clinical concern since they are associated with frequent treatment failure and high-40 rates of morbidity and mortality. The preservation of last-resort antibiotics that can be used to treat these formidable pathogens is of critical importance. 41

42

43 *Enterococcus faecium* is one such formidable pathogen. It is a commensal of the human 44 gastrointestinal tract that has emerged as a major nosocomial pathogen⁵. The intrinsic 45 antibiotic resistance of hospital-associated clones coupled with their ability to rapidly acquire 46 additional antibiotic resistance genes makes *E. faecium* infections increasingly difficult to 47 treat⁶. In particular, strains resistant to vancomycin, the first-line antibiotic for invasive 48 infections, have emerged and disseminated globally due to the acquisition of transferable *van*

resistance genes⁷. Consequently, *E. faecium*, which is one of the ESKAPE pathogens
(*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter spp*.), has been recognised by the
World Health Organization (WHO) as a 'high priority' bacterial pathogen⁸.

53

54 The lipopeptide daptomycin is a WHO designated 'last-resort' antibiotic that is used 'off-label' 55 to treat severe vancomycin-resistant *E. faecium* (VREfm) infections⁹. The increasing reports 56 of daptomycin-resistant VREfm are of great clinical concern. The specific risk factors for 57 acquiring a daptomycin-resistant VREfm strain are poorly understood, however, patients with 58 a daptomycin-resistant, bloodstream isolate are generally more likely to have been exposed to daptomycin^{10,11}. Daptomycin resistance in clinical strains is commonly associated with the 59 60 presence of specific mutations in the regulatory system LiaRS and cardiolipin synthase Cls¹²⁻ 61 ¹⁴. However, many daptomycin-resistant VREfm contain wild-type (WT) *liaRS* and *cls* alleles, 62 indicating other unknown molecular pathways are involved^{13,15,16}.

63

64 In Australia, high rates (15%) of daptomycin-resistant VREfm were recently reported¹⁷, but 65 the data were not epidemiologically robust and genetic determinants leading to resistance 66 were not defined. Accordingly, we undertook a combined genomic and phenotypic analysis 67 to investigate the daptomycin resistance mechanisms in VREfm. Here we show that 68 daptomycin resistance can emerge de novo in VREfm following exposure to rifaximin, a commonly prescribed antibiotic used prophylactically to prevent hepatic encephalopathy¹⁸ in 69 70 liver disease patients. Further, we show that rifaximin-mediated daptomycin resistance is linked with the presence of novel mutations (G482D, H486Y, and S491F) within the rifampicin-71 72 resistance determining region (RRDR) of RpoB. Importantly, patients given rifaximin were 73 significantly more likely to harbour daptomycin-resistant VREfm (that also carried RpoB 74 mutations) than patients who did not receive rifaximin. Finally, we show that the identified 75 RpoB mutations arose within the VREfm population soon after rifaximin was first approved 76 for clinical use and have since become globally established, with three independent VREfm 77 lineages currently circulating within at least 20 countries. Our work has therefore uncovered 78 a major new mechanism of daptomycin resistance in VREfm and identified rifaximin, an 79 antibiotic considered to be low-risk for the emergence of bacterial resistance¹⁹, as an 80 important driver of last-resort antibiotic resistance.

81

82 Results

Baptomycin resistance in Australian VREfm is polygenic and does not correlate with known
 resistance determinants.

Daptomycin susceptibility testing was performed on VREfm isolated during two unbiased 85 86 state-wide 'snapshot' studies undertaken for month-long periods in 2015 (n=294) and 2018 87 (n=423) in Victoria, Australia. The proportion of isolates resistant to daptomycin was 16.6% 88 (n=49) in 2015 and 15.3% (n=65) in 2018. Given the unexpectedly high rate of resistance 89 observed, we expanded the study to include additional VREfm isolated in 2017 (n=108) and 2018 (n=173) as part of the 'Controlling Superbugs' flagship study^{20,21}, with 28.4% (n=80) of 90 91 these isolates being resistant to daptomycin. Overall, we observed 189 (18.9%) daptomycin-92 resistant VREfm isolates, indicating a very high prevalence of daptomycin resistance in 93 Victoria, Australia.

94

95 To investigate the relationship between daptomycin-resistant and daptomycin-susceptible
96 VREfm, whole-genome comparisons were made for the 998 study isolates plus two additional

97 finished VREfm genomes (one daptomycin-susceptible and one daptomycin-resistant). A 98 maximum-likelihood phylogeny was inferred from an alignment of 6,574 core genome single 99 nucleotide polymorphisms (SNPs) (Supplementary Figure 1). In silico multi-locus sequence typing identified 36 sequence types (STs) within the 1000 isolates; 30 of these STs included at 100 101 least one of the 189 daptomycin-resistant VREfm. Daptomycin resistance was interspersed 102 throughout the tree (i.e. mostly polyphyletic), with several distinct clades. The largest clade 103 (ST203) of daptomycin-resistant strains, accounted for 42.3% of resistant isolates (n=80 of 104 189) and consisted of a single clone predominant during our sampling timeframe (2015 to 105 2018), suggestive of an expanding daptomycin-resistant lineage. The other predominant STs 106 (ST80, ST796, ST1421, and ST1424) consisted of several groups of resistant isolates that did 107 not cluster based on tree structure. The presence of daptomycin-resistant isolates in distinct 108 genetic backgrounds suggested daptomycin resistance has arisen independently within this 109 VREfm population on multiple occasions.

110

111 Given the high prevalence of daptomycin resistance in Australian VREfm isolates, we sought 112 to determine the genetic determinants leading to resistance. Only seven daptomycinresistant isolates (3.7%) contained the dual LiaR W73C and LiaS T120A mutations. This finding 113 114 is of note since current literature suggests these mutations are the most important mechanism of daptomycin resistance in VREfm^{9,12,22}. In addition, no daptomycin-resistant 115 116 isolates contained the H215R or R218Q mutations in Cls or the Q75K mutation in the septum 117 site determining protein (DivIVA), which have all previously been linked with daptomycin 118 resistance in VREfm²³. The mechanism of daptomycin resistance in the majority (n=182) of our resistant study isolates was therefore left largely unexplained by previously characterised 119 120 mutations.

121 The S491F mutation in RpoB is a novel mediator of daptomycin resistance in VREfm.

122 To identify the mutations associated with daptomycin resistance in our study isolates, we 123 performed a genome-wide association study (GWAS) approach on the collection of 1,000 124 VREfm isolates with known daptomycin MIC (Figure 1A). To account for the clonal population 125 structure of the collection, we first removed non-homoplastic variants from the list of core 126 genome mutations to reduce the data set to variants that were acquired at least twice across 127 the phylogeny. We then applied a linear mixed model using a kinship matrix as a random 128 effect. After correcting for multiple testing, the analysis identified 142 mutations (in 73 genes) significantly ($P < 1x10^{-10}$) associated with daptomycin resistance (as a binary variable with a 129 130 breakpoint of 8 mg L⁻¹). The top five most significant mutations were (i) I274S in an uncharacterised ABC efflux protein ($P = 7.44 \times 10^{-15}$), (ii) G71S in an uncharacterised permease 131 protein ($P = 7.77 \times 10^{-14}$), (iii) V288L in a mannitol dehydrogenase protein ($P = 6.08 \times 10^{-12}$), (iv) 132 S491F in RpoB, which is the RNA polymerase ß subunit (P=1.57x10⁻¹³), and (v) T634K in RpoC, 133 134 which is the RNA polymerase β' subunit (*P*=4.40x10⁻¹¹).

135

136 Deletion of the genes encoding the ABC efflux protein, permease protein, or mannitol 137 dehydrogenase protein had no impact on daptomycin susceptibility in a clinical daptomycin-138 susceptible strain of VREfm from the ST796 genetic background. Similarly, introduction of the 139 T634K mutation within RpoC did not lead to increased levels of daptomycin resistance. 140 However, introduction of the S491F substitution within RpoB, resulted in a 4-fold increase in daptomycin MIC, from 2 mg L⁻¹ to 8 mg L⁻¹, and a daptomycin-resistant phenotype. Since 141 142 mutations within rpoB have previously been associated with daptomycin resistance in Staphylococcus aureus^{24,25}, we focused further experimental investigations on the RpoB 143 144 S491F mutation.

145

Based on amino acid alignment, the S491F mutation is located within the predicted RRDR of *E. faecium* RpoB, which spans amino acids 467 to 493 (inclusive). The majority of study isolates (n=829, 82.9%) contained a WT RRDR; however, 169 (16.9%) VREfm contained at least one mutation within this region (Figure 1B), with the S491F mutation being the most common (n=105). This was followed by H486Y (n=16), G482D (n=12), G482V (n=10), Q473L (n=6), H486R (n=5), and other uncommon (n=3) mutations.

152

153 Different mutations within the RRDR of RpoB result in daptomycin resistance in VREfm.

154 Given the association of the S491F mutation in RpoB with daptomycin resistance, we hypothesised that other mutations within RpoB may also alter daptomycin susceptibility 155 156 (Figure 1B). In keeping with this hypothesis, we observed a putative correlation between 157 strains carrying individual G482D (n=12) and H486Y (n=16) mutations in RpoB and daptomycin 158 resistance, with 10 daptomycin-resistant isolates containing G482D (83.3% resistant) and 13 159 containing H486Y (81.3% resistant). Clinical isolates containing the G482D, H486Y, or S491F 160 mutations were interspersed throughout the phylogenetic tree and identified in distinct STs, highly suggestive of multiple independent acquisitions (Figure 1C). Ongoing expansion was 161 162 also observed for one dominant, daptomycin-resistant clone (ST203) containing the S491F 163 mutation throughout the isolate collection period (2015-2018).

164

The G482D and H486Y mutations were also located within the predicted RRDR region, suggesting a potential correlation between rifamycin and daptomycin resistance. Therefore, rifampicin susceptibility testing (with rifampicin being a marker of rifamycin resistance²⁶) was performed on all clinical VREfm containing a RpoB mutation within the predicted RRDR

(n=169). A randomly selected collection (n=169) of isolates containing a WT RpoB RRDR were used as a control group in this analysis. Mutations located within the predicted RRDR correlated with high-level rifampicin resistance (median MIC 256 mg L⁻¹), while control isolates containing the WT region displayed a median MIC of 8 mg L⁻¹ (Supplementary Figure 2). The correlation between rifampicin and daptomycin resistance in clinical strains containing the G482D, H486Y, and S491F mutations, suggested a novel link between rifamycin and daptomycin resistance in VREfm.

176

177 To confirm the G482D and H486Y mutations in RpoB also led to rifamycin and daptomycin 178 resistance we constructed isogenic mutants carrying these mutations in the same rifamycin-179 susceptible, daptomycin-susceptible, clinical strain of VREfm (ST796), used to make the S491F 180 RpoB isogenic mutant above. Introduction of the G482D, H486Y, or S491F RpoB mutations resulted in a 7-fold decrease in rifampicin susceptibility compared to the WT strain, leading 181 182 to high-level rifampicin resistance (>512 mg L⁻¹) (Figure 1D). To confirm the changes in 183 rifampicin susceptibility were due to the introduction of each specific mutation and not 184 unknown secondary mutations, we reverted each RpoB mutation to WT by restoration of the 185 chromosomal allele. Complementation to the WT rpoB allele in each of the G482D, H486Y, or 186 S491F mutants resulted in reversion of rifampicin MIC to the WT level (8 mg L⁻¹), indicating 187 the RpoB mutations were responsible for the heightened levels of rifampicin resistance 188 observed (Figure 1D). To then determine if the G482D and H486Y mutations could also cause 189 daptomycin resistance, daptomycin susceptibility testing was performed. Similar to the S491F 190 isogenic strain, introduction of the G482D or H486Y mutation resulted in a 4-fold increase in daptomycin MIC, from 2 mg L⁻¹ to 8 mg L⁻¹, and a daptomycin-resistant phenotype (Figure 1E). 191 192 Complementation with the WT rpoB allele onto the chromosome resulted in reversion of

daptomycin MIC to the WT level, indicating the G482D, H486Y, and S491F RpoB mutations
 resulted in cross-resistance to rifamycins and daptomycin in VREfm.

195

196 Given the reported importance of *liaRS* mutations in daptomycin-resistant VREfm, we also 197 introduced the well-characterised LiaR W73C and LiaS T120A mutations into the same clinical 198 strain of VREfm (Figure 1D). No difference in rifampicin MIC was observed after introduction 199 of the *liaRS* mutations, compared to the WT strain, indicating the cross-resistance observed 200 with the G482D, H486Y, and S491F mutations is unique to these RpoB substitutions. However, 201 compared to the WT, introduction of the *liaRS* mutations decreased daptomycin susceptibility 202 2-fold, with a reversion to the WT daptomycin MIC after complementation with the WT liaRS 203 alleles. The introduction of the *liaRS* mutations had less of an impact on daptomycin 204 susceptibility than the G482D, H486Y, and S491F RpoB mutations and did not result in a 205 daptomycin-resistant phenotype (MIC \geq 8 mg L⁻¹). When considered in conjunction with the 206 genomic epidemiology data associated with this study, where *liaRS* mutations were less 207 common than the rpoB mutations in daptomycin-resistant VREfm (n=7 versus n=141, 208 respectively), our data suggests that mutations within RpoB might represent a previously uncharacterised, yet important mechanism of daptomycin resistance in VREfm. 209

210

211 The G482D, H486Y and S491F RpoB mutations are common in international VREfm strains.

To determine if the *rpoB* mutations associated with daptomycin resistance observed in Australian VREfm were representative of other VREfm isolates globally, we performed a largescale analysis using publicly available VREfm sequence data from healthcare-associated strains (n=4,476; n=3,476 international and n=1,000 Australian) (Figure 2A). Of the isolates analysed, 630 (14.3%) carried an amino acid substitution in the RRDR of RpoB, occurring at 16

positions (Figure 2B). The S491F mutation was the most common, being present in 461 isolates, and accounting for 77.9% of the RpoB mutations observed. Isolates carrying this mutation originated from 20 countries, and *in silico* MLST showed the mutations were spread across 21 different STs, with ST203 (44.7%), ST80 (30.2%), and ST117 (11.5%) accounting for the majority (86.4%) of isolates carrying this substitution. Importantly, five VREfm harbouring the S491F mutation also contained the *cfr(B)* (n=4) or *poxtA* (n=1) genes that confer resistance to linezolid, suggesting near pan-resistant strains of VREfm have already emerged.

224

225 The H486Y mutation was the second most common, and was identified in 73 isolates, 226 equivalent to 11.6% of strains with mutations within the RRDR of RpoB. These isolates were 227 collected from 10 countries and *in silico* MLST identified 22 STs, with the most common being 228 ST203 (23.2%), ST796 (21.9%), and ST80 (20.5%). The G482D mutation was the third most 229 common, being identified in 43 isolates, and accounting for 6.8% of strains carrying RpoB 230 mutations. It was present in nine distinct STs, although mostly commonly in ST796 (65.1%) 231 and ST1421 (11.6%), and was identified in isolates from seven countries. Collectively, these 232 data indicated the G482D, H486Y, and S491F mutations, which confer cross-resistance to 233 rifamycins and daptomycin, are not restricted to Australian VREfm but are globally prevalent 234 in healthcare-associated VREfm strains.

235

To determine whether the identified RpoB mutations were enriched within healthcareassociated VREfm (established as clade A1), we interrogated publicly available genomic sequences of VREfm from clade A2 (n=98), known for being animal-associated²⁷. In keeping with previous findings, the maximum-likelihood tree clustered isolates into two main clades: one healthcare-associated and one associated with VREfm from animals. No mutations were

identified in the RpoB RRDR region of strains isolated from animals, with our analyses showing
that RRDR RpoB mutations were significantly (*P*<0.001; Fisher's exact test) associated with
healthcare-associated VREfm. This suggests the identified RpoB mutations are primarily
enriched within the healthcare setting (Supplementary Figure 3).

245

Phylodynamics indicate the S491F RpoB mutation emerged within the VREfm population
following the clinical approval of rifaximin.

248 Given the predominance of the S491F mutation in globally distributed VREfm populations, we 249 used evolutionary phylodynamic analyses to understand its emergence. Within our Australian 250 isolates, we observed the expansion of a dominant ST203 clone from 2015 to 2018 that 251 carried the S491F mutation (Figure 1C). Since this clone comprised VREfm carrying the vanA 252 resistance cluster or operon, we sequenced all "historical" vanA-VREfm from our public health 253 laboratory (n=229), which consisted of every vanA-VREfm isolate collected from 2003 to 254 2014, to increase temporal signal. We then contextualised all Australian isolates (n=1,229) 255 with the international (n=3,389) VREfm in a maximum-likelihood phylogeny inferred from an 256 alignment of 9,277 SNPs and used clustering with core-genome MLST (cgMLST) to identify 257 three clusters containing the RpoB S491F mutation (Figure 3A). The same ST203 clone (Cluster 258 1) formed the largest cluster (n=219 taxa), consisting of isolates from Australia and United 259 Kingdom. Cluster 2 (n=85 taxa) consisted of ST80 and ST78 isolates from Australia, Europe, 260 South America, the United Kingdom, and the United States of America while Cluster 3 (n=68 261 taxa) consisted of ST80 isolates from Australia, Europe, and the United Kingdom.

262

263 To model the evolutionary trajectories of these three VREfm clusters, we used core-genome
264 SNP diversity and year of isolation (Figure 3B). Bayesian phylodynamic analyses were

conducted using the core-genome SNP alignments for each cluster/lineage with a discrete 265 266 trait model and constant coalescent tree prior. We assessed for temporal signal within each 267 cluster using a root-to-tip regression (Supplementary Figure 4). The substitution rate (the number of expected substitutions per site per year) was consistent with other estimates for 268 healthcare-associated VREfm, otherwise referred to as clade A1^{27–30}. The median substitution 269 270 rate was similar for Cluster 1 and Cluster 2, at 9.7x10⁻⁷ [95% highest posterior density (HPD) $6.88 \times 10^{-7} - 1.24 \times 10^{-6}$ and 1.25×10^{-6} (95% HPD 7.68×10⁻⁷ - 1.74×10⁻⁶) respectively, but slightly 271 272 faster for Cluster 3 at 3.86×10^{-6} (95% HPD $2.23 \times 10^{-6} - 5.69 \times 10^{-6}$). The year of emergence for 273 the most recent common ancestor (MRCA) was estimated for each cluster to indicate when 274 the RpoB S491F mutation was first acquired. The MRCAs for the clusters were similar, with 2006 (HPD 1993 – 2012) for Cluster 1, 2000 (HPD 1989 – 2008) for Cluster 2, and 2004 (HPD 275 276 2001 – 2010) for Cluster 3, suggesting the lineages emerged at similar times (Figure 3C).

277

278 Given the association of the S491F mutation in RpoB and rifamycin resistance, we 279 hypothesised rifamycin use might be driving the emergence of this mutation. The most 280 commonly used rifamycin antibiotics in clinical practice are rifampicin and rifaximin. Since 281 rifampicin was approved for clinical use by the United States Federal Drug Administration 282 (FDA) in 1971, several decades before the estimated emergence of the MRCAs, it is unlikely 283 to have played a major role in the emergence of the S491F mutation within this VREfm 284 population. However, the MRCA for all three clusters is predicted to have emerged around 285 the same time as the first clinical introduction of rifaximin, in 2004. The acquisition of the 286 same mutation in three genetically distinct lineages at a similar time, provides support for our hypothesis that rifamycin use might be driving selection of the S491F mutation within VREfm. 287 288 Further, the structure of the three maximum clade credibility (MCC) trees (Figure 3B)

suggested the lineages have expanded over time, which may be correlated with the approval
and subsequent widespread, international use of rifaximin for the prevention of hepatic
encephalopathy since 2010 (Figure 3B).

292

The S491F mutation in Cluster 1 and Cluster 2 was found to be stably maintained within each 293 294 lineage after its acquisition, with few high probability events of reversion to the WT rpoB 295 allele, indicative of maintenance after emergence (Supplementary Figure 5A-B). For Cluster 296 3, the RpoB S491F mutation emerged a single time, with high (~0.95) posterior probability of 297 a single acquisition within the cluster and subsequent maintenance (Supplementary Figure 298 5C). There was also an equal posterior probability of either a second acquisition within the 299 cluster or loss of the RpoB S491F mutation within Cluster 3. Overall, the Markov jumps for all 300 three clusters suggests that the S491F mutation emerged and was then subsequently 301 maintained within these globally prevalent lineages. Taken together these data show the 302 S491F mutation has emerged within the VREfm population on several occasions since the 303 early 2000s, with the predicted dates of emergence being closely correlated with the clinical 304 introduction of rifaximin.

305

Rifaximin drives the emergence of daptomycin-resistant VREfm in a murine model of gastrointestinal colonisation.

Rifaximin is a non-absorbable oral agent with direct antimicrobial activity in the gastrointestinal tract. It is predominately used to prevent recurrent hepatic encephalopathy in patients with liver cirrhosis^{18,31}. Importantly, this patient cohort is high-risk for VREfm colonisation within the gastrointestinal tract³². Since the Bayesian phylodynamic analyses highlighted a putative correlation between the S491F RpoB mutation in VREfm and use of 313 rifaximin, we hypothesised rifaximin use may be driving the emergence of this mutation and 314 therefore, daptomycin-resistant VREfm within the gastrointestinal tract of patients receiving 315 this antibiotic. To test this hypothesis, mice were colonised with a clinical, daptomycin-316 sensitive (MIC 2 mg L⁻¹) VREfm strain (Aus0233) containing a WT rpoB gene before being 317 administered a human-equivalent dose of rifaximin, rifampicin, daptomycin, or vehicle (Figure 318 4A and Supplementary Figure 6). Rifampicin was chosen as a comparison since it is also a 319 commonly used rifamycin in clinical practice. After 7 days of rifamycin treatment, we 320 observed rifamycin-resistant VREfm in significantly more mice receiving rifaximin (90% of 321 mice) or rifampicin (80% of mice) than in mice that received daptomycin (0% of mice) (P < 322 0.0001 and *P* < 0.0001; unpaired *t*-test) or vehicle (0% of mice) (*P* < 0.0001 and *P* < 0.0001; 323 unpaired *t*-test) (Figure 4B).

324

For each mouse, we then determined the percentage of individual VREfm isolates that were 325 326 rifamycin-resistant or daptomycin-resistant. There were significantly more rifamycin-327 resistant VREfm isolated from mice receiving rifaximin or rifampicin than mice receiving the 328 vehicle control (P < 0.001 and P < 0.01; unpaired *t*-test) or daptomycin (P < 0.001 and P < 0.01; 329 unpaired *t*-test) (Figure 4D). Similarly, there was significantly more daptomycin-resistant 330 VREfm in mice receiving rifaximin or rifampicin than vehicle control (P < 0.05 and P < 0.05; 331 unpaired *t*-test) or daptomycin (P < 0.05 and P < 0.05; unpaired *t*-test) (Figure 4E). We 332 estimated that daptomycin-resistant VREfm accounted for between 0-41% of the 333 gastrointestinal VREfm population in mice given rifaximin and 0-36% in mice given rifampicin, 334 demonstrating conclusively that rifamycin administration can drive the emergence of VREfm with cross-resistance to rifamycins and daptomycin. Notably, no daptomycin-resistant VREfm 335 were isolated from mice receiving daptomycin, in agreement with prior research³³. 336

337

338 To identify which mutations were present in the rifamycin-resistant VREfm isolates collected 339 from mice administrated either rifaximin or rifampicin, we randomly selected 150 isolates 340 from each antibiotic group (rifaximin or rifampicin, n=300 total) to undergo WGS, consisting 341 of 100 rifamycin-resistant isolates collected following the last day of treatment and 50 isolates 342 from before rifaximin or rifampicin administration. No mutations in RpoB were identified in 343 any VREfm isolate collected prior to rifaximin or rifampicin exposure. However, following the 344 administration of either rifaximin or rifampicin, VREfm carrying mutations within RpoB were 345 commonly identified. The S491F mutation was most abundant (n=53 and 63, respectively), 346 with all isolates carrying this mutation being daptomycin-resistant (Figure 4F). The H486Y 347 mutation was also commonly identified, albeit less so than S491F, (n=12 and 28, respectively), 348 with all isolates again being daptomycin-resistant. The G482D mutation was the third most commonly identified RpoB mutation (n=15 and 6, respectively), with 13 isolates carrying this 349 350 mutation being daptomycin-resistant. Note that 2 isolates containing the G482D mutation in 351 the rifampicin treated mice were daptomycin-sensitive, likely due to other confounding 352 mutations within the genome. Other RpoB mutations in addition to S491F, H486Y, and G482D 353 were also identified. These included V135F, L471V, E473L, and H486A, however all VREfm 354 isolates carrying these mutations were daptomycin-sensitive. Importantly, the proportions of 355 each RpoB mutation observed in VREfm collected from the gastrointestinal tract of mice 356 administered either rifaximin or rifampicin, correlated closely the proportions of each 357 mutation observed in our collection of human clinical VREfm isolates, with the S491F 358 mutation most commonly identified, followed by H486Y, and then G482D, suggesting a similar selective pressure (i.e. rifamycin use) found in our mouse experiments might be driving 359 360 the emergence of similar RpoB mutations within human clinical isolates. Taken together, these data demonstrate that exposure to rifaximin can drive the emergence of daptomycin
resistance in colonising strains of VREfm, through the enrichment of isolates carrying select
mutations in RpoB.

364

365 VREfm collected from patients receiving rifaximin are more likely to be daptomycin-366 resistant than VREfm collected from patients that did not receive rifaximin.

367 To further test our hypothesis that rifaximin use might be driving the emergence of daptomycin resistance in VREfm, we performed a case-control analysis of clinical VREfm 368 369 isolates collected from a retrospective cohort of patients from a single tertiary healthcare 370 centre in Melbourne, Australia over 4 years. The VREfm isolates were stratified according to 371 whether the patient had received rifaximin within 1 month of VREfm isolate collection or not. 372 A total of 50 VREfm strains were identified as being from patients receiving rifaximin. As a 373 control group, we randomly selected 50 VREfm that had been collected from patients that 374 had not received rifaximin. The majority (88%) of these VREfm were screening samples. All 375 isolates were collected over the same time frame and from the same institution.

376

A maximum-likelihood phylogeny was inferred from an alignment of 12,430 core-genome 377 378 SNPs (Figure 5A). The VREfm isolates in the rifaximin and control groups were dispersed 379 throughout the tree, with 5 different STs (ST78, ST80, ST203, ST796, ST1421, and ST1424) 380 from rifaximin patients and 6 different STs (ST17, ST78, ST80, ST203, ST796, ST1421, and 381 ST1424) from the control patients. There were 28 VREfm from the rifaximin group that 382 contained a mutation within the RRDR of RpoB, with 17 containing the S491F mutation, 5 G482D, 4 H486Y, 1 E473L, and 1 G482V mutation. All isolates containing the S491F, H486Y, 383 384 and G482D mutations were resistant to daptomycin, while isolates with the E473L and G482V

385	mutations were daptomycin-susceptible. The control group had 2 isolates with RRDR RpoB
386	mutations, with 1 susceptible isolate containing a D476Y and 1 daptomycin-resistant isolate
387	containing the S491F substitution.

388

Rifaximin exposure in patients was significantly correlated with the isolation of a rifamycinresistant (*P* = 0.00007, OR = 60.0, 95% CI = 8.8 – 2562.1; Fisher's Exact Test) and daptomycinresistant VREfm strain (*P* = 0.0006, OR = 25.0, 95% CI = 5.5 – 235.3; Fisher's exact test) (Figure 5B and C). These data indicated that patients receiving rifaximin are significantly more likely to carry rifamycin-resistant and daptomycin-resistant strains of VREfm than patients who did not receive rifaximin, suggesting rifaximin use might be an important driver in the *de novo* emergence and spread of daptomycin-resistant VREfm.

396

397 Discussion

398 In this study we have shown that specific mutations within the RRDR of RpoB represent a new, 399 major mechanism of daptomycin resistance in VREfm. Our analyses demonstrate these 400 mutations are globally distributed within the VREfm population and are as prevalent as other 401 well-characterised mutations within LiaRS and Cls, which have been previously associated with daptomycin resistance in VREfm and assumed to be the dominant mechanisms^{22,34,35}. 402 403 Given the similar prevalence, as well as the finding that isogenic mutants carrying the G482D, 404 H486Y or S491F RpoB mutations display a greater level of daptomycin resistance than isogenic 405 strains carrying mutations in LiaRS, the RpoB mutations discovered here add to the list of 406 clinically relevant mutations involved in the emergence of daptomycin-resistant VREfm.

407

408 Our data suggest the S491F substitution is the dominant RRDR RpoB mutation in VREfm and 409 is present in at least three phylogenetically distinct lineages currently circulating within 410 healthcare systems globally, including in Australia, the United Kingdom, the United States of America, and across Europe. The extent of their dissemination is likely to be underestimated 411 412 in regions with limited representation in our analyses, such as in Asia, Africa, and South 413 America. It is of clinical concern these lineages have successfully spread over geographic 414 scales and persisted for at least 15 years, since it suggests these globally prevalent lineages 415 might eventually compromise the therapeutic value of daptomycin for treating VREfm 416 infections. The Bayesian analyses provide support the S491F mutation emerged after the first 417 introduction of rifaximin for clinical use, for treatment of travellers' diarrhea, with each of the 418 MCC trees suggestive of subsequent population expansion. In 2010, rifaximin was shown to 419 be efficacious for the prevention of recurrent hepatic encephalopathy in patients with chronic 420 liver disease¹⁸ resulting in a marked increase in its clinical use. As this patient cohort is 421 predisposed to gastrointestinal VREfm colonisation, we hypothesise that the use of rifaximin 422 in this cohort has driven the population expansion of the S491F mutation in VREfm over 423 subsequent years. Further, our data suggests rifampicin is not a significant driver of these 424 RpoB mutations since therapeutic use of rifampicin has occurred since the 1970s and the 425 emergence of VREfm containing these mutations is much more recent. However, 426 appropriately controlled clinical cohort studies will be needed to test these hypotheses.

427

VREfm isolates carrying the G428D, H486Y and S491F RpoB mutations were resistant to rifamycin antimicrobials, in addition to daptomycin. Mutations within the RRDR of RpoB have been associated with rifamycin resistance in numerous bacterial species²⁶, with exposure to rifamycins being a well-documented driver in the emergence of rifamycin-resistant clones in

432 Staphylococcus^{36–38}. In keeping with this observation, our data suggests the clinical use of 433 rifaximin may be responsible for selecting VREfm isolates harbouring mutations within the 434 RRDR of RpoB and therefore, indirectly driving the emergence of daptomycin-resistant 435 VREfm. Three lines of evidence support our hypothesis: (i) Bayesian phylodynamic analyses 436 show the emergence of phylogenetically distinct VREfm lineages carrying the S491F is 437 temporally linked with the clinical approval of rifaximin in the early 2000s, (ii) animal 438 experiments demonstrated the administration of rifaximin to mice colonised with VREfm led 439 to the emergence of VREfm strains within the gastrointestinal tract that carried mutations 440 within RRDR of RpoB and were resistant to rifamycins and daptomycin, and (iii) an analysis of 441 clinical VREfm isolated from humans showed patients receiving rifaximin were significantly 442 more likely to carry VREfm strains harbouring mutations within the RRDR of RpoB that were 443 resistant to both rifamycins and daptomycin, compared to patients that did not receive rifaximin. It is therefore plausible that rifaximin exposure in this patient cohort might be an 444 445 important factor in the increasing rates of daptomycin-resistant VREfm that are currently being reported^{17,39}, through the *de novo* emergence of the RpoB mutations and/or ongoing 446 447 transmission of resistant strains carrying these mutations. Appropriately controlled clinical 448 cohort studies are needed to dissect this hypothesis. Importantly, given the high rates of 449 daptomycin resistance observed, our results suggest daptomycin should not be used for 450 empiric therapy of invasive VREfm infections in patients who are receiving rifaximin.

451

452 Of note is our observation that rifaximin exposure in mice led to the emergence of strains 453 carrying similar RRDR RpoB mutations to those observed in human clinical isolates and the 454 relative abundance of these mutations within isolates collected from the gastrointestinal tract 455 of mice exposed to rifaximin closely resembled the relative abundance of these mutations in

456 our collection of human VREfm, with S491F, G482D and H486Y being the most abundant
457 mutations in both cases. These observations are suggestive of similar selective pressures,
458 such as rifaximin exposure, being at play in both the controlled mouse experiments of our
459 study and in the human population.

460

461 Overall, this research highlights the potentially serious collateral damage that can arise 462 following the introduction of new clinical antibiotic regimens. While the emergence of within-463 family antibiotic resistance resulting from prophylactic antibiotic use has been described previously^{40,41}, there are relatively few studies³⁷ suggesting that prophylactic antibiotics, such 464 465 as rifaximin, can lead to cross-resistance between unrelated and last-resort antibiotics, as shown here. Careful consideration should therefore be given to the potential impact of 466 prophylactic antibiotics on antimicrobial stewardship practices. Current thinking⁴² 467 recommends withholding the use of last-resort antibiotics to limit the emergence and spread 468 469 of resistance. However, our findings suggest this is not always the case, since gastrointestinal 470 rifaximin exposure can lead to the emergence of daptomycin-resistant VREfm in the absence 471 of daptomycin. Appropriate surveillance for patients colonised in the gastrointestinal tract 472 with nosocomial pathogens and receiving antibiotic treatment for secondary or unrelated 473 conditions is therefore of critical importance in limiting the emergence and spread of new 474 and increasingly antibiotic-resistant clones within the hospital environment.

475

In conclusion, we have identified a new, globally important mechanism of last-resort antibiotic resistance in VREfm and show that prophylactic rifaximin use is a likely driver of this resistance. These findings demonstrate the ease with which new antibiotic treatment regiments can drive the emergence of novel multidrug resistant pathogens and highlight the

- 480 negative impact that unanticipated antibiotic cross-resistance can have on antibiotic
- 481 stewardship efforts designed to preserve the use of last-resort antibiotics. We advocate for
- 482 the judicious use of all antibiotics.

483

484 Methods

485 Media and reagents

486 *E. faecium* was routinely cultured at 37°C in brain heart infusion (BHI) broth (Becton Dickson) 487 or BHI agar (BHIA), BHI solidified with 1.5% agar (Becto Dickson). For electroporation, E. 488 faecium was cultured in BHI supplemented with 3% glycine and 200 mM sucrose (pH 7.0). 489 Escherichia coli was cultured in Luria broth (LB). Broth microdilution (BMD) MICs were 490 performed in cation-adjusted Mueller Hinton with TES broth (CAMHBT) broth (Thermo 491 Fisher). A concentration of 10 mg L⁻¹ chloramphenicol (Sigma Aldrich) was used for plasmid 492 selection in E. faecium and E. coli. The following antibiotics were used at variable 493 concentrations for susceptibility testing: rifampicin (Sigma Aldrich), rifaximin (Sigma Aldrich), 494 and daptomycin (Cubicin).

Oligonucleotides were purchased from Integrated DNA Technologies and are listed in
Supplementary Table 1. Plasmids were purified with Monarch Plasmid Miniprep Kit (NEB).
PCR products and gel extractions were purified using Monarch DNA Gel Extraction Kit (NEB).
Genomic DNA was purified using the Monarch Genomic DNA Purification Kit (NEB). Phusion
and Phire DNA polymerase was purchased from New England Biolabs.

500 Bacterial isolates

501 Bacterial strains used in this study are listed in Supplementary Table 2. Australian bacterial 502 strains were collected across three data projects in the Microbiological Diagnostic Unit Public 503 Health Laboratory (MDU PHL). Two unbiased cross-sectional surveys of VREfm were 504 conducted between 10 November and 9 December 2015 (n=331)⁴³ and between 1 November 505 and 30 November 2018 (n=323) in the State of Victoria (referred to as the 2015 and 2018 506 Snapshot). During this period, all VREfm-positive isolates (including screening and clinical 507 samples) collected by laboratories across the state were sent to the MDU PHL. In addition, this project included *vanA*-VREfm collected from the "Controlling Superbugs" study²⁰, a 15month (April-June 2017 and October 2017-2018) prospective study including eight hospital
sites across four hospital networks, resulting in 346 VREfm isolates (308 patients) sent for
WGS at MDU PHL. The VREfm were isolated from patient samples (including screening and
clinical samples) routinely collected from hospital inpatients. For the 'historical *vanA*-VREfm,'
every *vanA* isolate collected within MDU PHL was included. This resulted in an additional 225
isolates, sampled between 2008 and 2014.

515 For publicly available isolates, our aim was to capture the diversity of *E. faecium* circulating 516 globally by including isolates that formed part of several key studies involving hospital-517 associated VREfm (as of January 2021). To be included, isolates needed to have short-read 518 data available, with geographic location (by country), year of collection, and source (human 519 or animal). Reads were only included if they had a sequencing depth of >50x. To capture the 520 diversity of VREfm circulating in the United States, isolates from human sources were 521 downloaded from the PathoSystems Resource Integration Center⁴⁴. All isolates were confirmed to be *E. faecium* with the Kraken2 database (v.2.1.2)⁴⁵. The final number of 522 523 international isolates compromised those from Africa (n=8), Asia (n=25), Europe (n=2941), 524 North America (n=424), and South America (n=78) (Supplementary Table 2).

525 Antibiotic susceptibility testing

526 Daptomycin susceptibility testing was performed using the BMD MIC method as according to 527 CLSI guidelines. In a 96-well plate, a two-fold dilution series (from 32 to 0.5 mg L⁻¹) of 528 daptomycin was made in 100 μ L volumes of CAMHBT, additionally supplemented with 50 mg 529 L⁻¹ Ca²⁺. An inoculum of 100 μ L *E. faecium* broth culture adjusted to 1 x 10⁶ CFU mL⁻¹ in 530 CAMHBT was then added to each well. After 24 hours incubation, the MIC was defined as the 531 lowest antimicrobial concentration that inhibited visible growth. All assays were performed

532	in biological triplicate, with the median MIC reported. In accordance with recent guidelines ⁴⁶				
533	isolates with a daptomycin MIC \geq 8 mg L ⁻¹ were considered to be daptomycin-resistant. A				
534	daptomycin-sensitive strain (AUS0085) ⁴⁷ and a daptomycin-resistant strain (DMG1700661) ¹				
535	were used as a control.				
536	Rifampicin susceptibility testing was performed using the BMD method in CAMHBT. High				
537	level rifampicin resistance was defined with a MIC > 32 mg L^{-1} . All susceptibility testing wa				
538	performed in triplicate.				
539	Whole-genome sequencing				
540	Genomic DNA was extracted from a single colony using a JANUS automated workstation				
541	(PerkinElmer) and Chemagic magnetic bead technology (PerkinElmer). Genomic DNA libraries				
542	were prepared using the Nextera XT kit according to manufacturer's instructions (Illumina,				
543	San Diego, CA, USA). Whole-genome sequencing was performed using Illumina NextSeq				
544	platform, generating 150 bp paired-end reads.				
545	The short reads of isolates sequenced at MDU-PHL are available on the NCBI Sequence Read				
546	Archive [BioProjects PRJNA565795 (Controlling Superbugs), PRJNA433676 (2015 Snapshot)				
547	and PRJNA856406 (2018 Snapshot), and PRJNA856406 (historical vanA isolates)].				
548	Phylogenetic analysis				
549	De novo assemblies of the genomes were constructed using Spades ⁴⁸ (v3.13). In silico MLST				
550	were determined using the program mlst with the efaecium database				
551	(https://github.com/tseemann/mlst). The 1000 Australian genomes as well as the 4,612				
552	Australian and international VREfm were mapped to the reference E. faecium genome				
553	AUS0085 isolated from a human bacteraemia infection in Victoria, Australia (NCBI accession				
554	CP006620) ⁴⁷ using snippy (https://github.com/tseemann/snippy) (v4.4.5), applying a minfra				

value of 10 and mincov value of 0.9. This reference was selected as it was a publicly available

556 complete genome collected locally and daptomycin-sensitive. A maximum likelihood 557 phylogenetic tree was inferred using IQ-TREE (v2.1.2) with a general time-reversible (GTR + 558 G4) substitution model, including invariable sites as a constant pattern and 1000 bootstrap 559 replicates. Recombination masking was not performed for species maximum likelihood trees 560 due to the small size of the resulting core alignment. All trees were mid-point rooted and 561 visualised in R (v4.0.3, https://www.r-project.org/) using phangorn⁴⁹ (v2.5.5), ape⁵⁰ (v5.4), 562 ggtree⁵¹ (v2.3.4), and ggplot (v3.3.2).

563 The genome assemblies of all isolates were screened for acquired antimicrobial resistance

564 determinants using abriTAMR (https://github.com/MDU-PHL/abritamr).

565 Genome-wide association study of daptomycin resistance

A GWAS approach was applied to identify genetic variants of daptomycin resistance in E. 566 567 faecium. A genotype matrix of SNPs was constructed and used as input to homoplasyFinder⁵² (v0.0.0.9) to determine the consistency index at each locus and kept mutations that had an 568 569 index of ≤0.5 (indicating at least two independent acquisitions across the phylogeny). We then 570 ran GWAS using daptomycin resistance as a binary trait, where isolates were categorised as 571 resistant if their daptomycin MIC was $\geq 8 \text{ mg L}^{-1}$. To correct for population structure, we used 572 the factored spectrally transformed linear mixed models (FaST-LMM) implemented in pyseer⁵³ (v.1.3.6), which computes a kinship matrix based on the core genome SNPs as a 573 574 random effect. The Bonferroni method was used to correct *P* values for multiple testing.

575 Core genome MLST (cgMLST) and clustering

576 cgMLST alleles for each isolate was defined using the public *E. faecium* cgMLST scheme⁵⁴ and 577 chewBBACA (v2.0.16), implemented locally in the COREugate pipeline (v2.0.4) 578 (<u>https://github.com/kristyhoran/Coreugate</u>). The pipeline determines the alleles of each core 579 gene for every isolate as defined by the specific pathogen scheme. The *E. faecium* cgMLST scheme contains 1,423 genes. The number of allelic differences between each isolate within this core set of genes is then determined. The cgMLST clusters were determined using single linkage clustering and a pairwise allelic difference threshold of ≤250. This threshold was chosen since it maximised diversity within clusters, to improve temporal sampling depth, while still clustering based on maximum-likelihood tree structure.

585 Phylodynamic analyses of the emergence of the S491F RpoB mutation in VREfm lineages

586 To investigate the emergence of the S491F mutation in RpoB in three different lineages, as 587 defined with cgMLST, we undertook further analysis on these clusters/lineages. From the 588 species-level maximum-likelihood tree (Figure 3A), three lineages/clusters were identifiable 589 by cgMLST due to their size (n>50) and presence of the S491F mutation. The three clusters 590 were analysed independently, such that individual core-genome SNP alignments were 591 generated, since this increased the length of the core alignment and number of sites 592 considered. Snippy (https://github.com/tseemann/snippy) (v4.4.5) was used to generate the 593 alignments for each cluster to the corresponding reference genome (AUSMDU00004024 for 594 cluster 1, AUSMDU00004055 for cluster 2, and AUSMDU00004142 for cluster 3). Each core 595 alignment used a within 'cluster reference' (complete genome of the same cluster) to 596 maximise core-SNP alignment length. The reference for each cluster was chosen since they 597 were a locally-collected, closed genome. Recombination was removed from the final 598 alignment using Gubbins⁵⁵ (v.2.4.1) to ensure modelling was only informed by SNPs with tree-599 like evolution within the core genome. Maximum-likelihood trees for each of the three 600 clusters were inferred from the core-SNP alignments [Cluster 1: (n=219 taxa) 329 SNPs; 601 Cluster 2: (n=85 taxa) 541 SNPs; Cluster 3: (n=68 taxa) 764 SNPs] with IQ-tree (v2.1.2)⁵⁶ with a general time-reversible (GTR+ Γ) substitution model, including invariable sites as a constant 602

603 pattern. Phylogenetic uncertainty was determined through 1000 nonparametric bootstrap604 replicates.

To investigate temporal signal in the three clusters of VREfm genomes, we first used TempEst⁵⁷ (v1.5). A root-to-tip regression analysis was performed on the root-to-tip branch distances within the three, cluster maximum-likelihood phylogenies as a function of year of collection, with the position of the root optimised according to the heuristic residual mean squared method.

610 The frequency of the emergence of the *rpoB* mutation in VREfm was inferred using a discrete trait model implemented in BEAST⁵⁸ (v1.10.4). Under this model the SNP alignments 611 612 are used to infer the evolutionary process (i.e. phylogenetic tree, time, and nucleotide 613 substitution model parameters) for the three clusters. The alignments all shared the HKY 614 substitution model with a gamma distribution for among-site rate variation, and a constantsize coalescent population prior²⁸. To avoid ascertainment bias due to using a SNP alignment, 615 616 the number of constant sites were taken into account for the likelihood calculations. The 617 molecular clock was a relaxed clock with an underlying lognormal distribution. The molecular 618 clock was calibrated using isolation dates for each genome by year of collection and the mean 619 clock rate is shared between all three alignments, but the model allows for the individual 620 alignments to have different standard deviations of the lognormal distribution and also 621 different branch rates. The mean molecular clock rate requires an explicit prior distribution, 622 for which we used a Γ distribution and a 0.95 quantile range of 4.9x10⁻⁶ and 1.1x10⁻⁴ 623 substitutions/site/year. This informative prior means that it acts as an additional source of 624 molecular clock calibration that can drive estimates, even in the absence of temporal signal. 625 The presence or absence of the S491F mutation in *rpoB* was used as a binary trait^{59,60}.

626 The trait model was shared between the three alignments, with the different Markov jumps

627 and rewards (ie changes of trait state and time spent in each state, respectively) recorded for 628 each of the three alignments. The posterior distribution of model parameters was sampled 629 using a Markov chain Monte Carlo of 100,000,000 iterations, sampling every 100,000 630 iterations. Two independent runs were run for the models. We assessed sufficient sampling from the stationary distributions by verifying the effective sample size of key parameters was 631 632 around or above 200. The final maximum-clade credibility (MCC) trees were visualised in R (v4.0.3, https://www.r-project.org/) using ggtree⁵¹ (v2.3.4). The Markov jumps for the *rpoB* 633 634 trait for each alignment were visualised in R (v4.0.3, https://www.r-project.org/).

635 **Reconstruction of clinical mutations by allelic exchange**

The *liaR*^{W73C}, *liaS*^{T120A}, *rpoC*^{T634K}, *rpoB*^{G482D}, *rpoB*^{H486Y}, or *rpoB*^{S491F} mutations were recombined 636 into the chromosomal copy of each gene in ST796 VREfm (Ef aus0233) by allelic exchange. 637 The *liaR*^{W73C} and *liaS*^{T120A} mutations were first introduced individually, then together. The 638 region encompassing each gene was amplified by SOE-PCR and recombined into pIMAY-Z⁶¹ 639 640 by the seamless ligation cloning extract (SLiCE)⁶² method and transformed into Escherichia coli IM08B⁶¹. The construct was transformed into electrocompetent VREfm⁶², with allelic 641 642 exchange performed as described previously⁶³. Allelic exchange was performed as described⁶³. Reversion of *liaR*^{W73C} and *liaS*^{T120A}, *rpoB*^{G482D}, *rpoB*^{H486Y}, or *rpoB*^{S491F} mutations 643 were completed using allelic exchange with a construct containing the respective wild-type 644 645 allele. To delete the ABC transporter protein (EFAU085 02633), permease protein 646 (EFAU02892), or mannitol dehydrogenase (EFAU02627) from the chromosome, deletion 647 constructs were PCR-amplified from Ef_aus0233 genomic DNA and allelic exchange 648 performed as described above. Genome sequencing and analysis of all mutants was conducted as described, with resulting reads mapped to the Ef aus0233 reference genome 649 and mutations identified using Snippy (https://github.com/tseemann/snippy) (v4.4.5). 650

651 VREfm in vivo gastrointestinal colonisation experiments

Female C57BL/6 mice at 6-8 weeks of age were purchased from WEHI and maintained in a specific-pathogen-free facility at the Peter Doherty Institute for Infection and Immunity. All animal handling and procedures were performed in a biosafety class 2 cabinet. Animal procedures were performed in compliance with the University of Melbourne guidelines and approved by the University's Animal Ethics Committee

657 The dose for each antibiotic was calculated using the FDA human conversion formula to ensure each mouse was given a human-equivalent dose⁶⁴. To establish gastrointestinal 658 colonisation of VREfm, mice were administered ceftriaxone (410 mg kg⁻¹ day⁻¹; AFT 659 660 Pharmaceuticals) via subcutaneous injection once daily for 7 days, followed by an antibiotic wean period of 24 hours. Mice were then inoculated with 10^6 VREfm in 100 μ l PBS by oral 661 gavage. Three days after VREfm inoculation, single-housed mice were administered either 662 rifaximin (113 mg kg⁻¹ administered twice daily; Sigma Aldrich), rifampicin (123 mg kg⁻¹ 663 664 administered once day; Sigma Aldrich), or vehicle (Corn oil with 10% DMSO) via oral gavage; 665 or daptomycin (50 mg kg⁻¹ administered once daily; Cubicin) via subcutaneous injection [this results in similar exposure (AUC₀₋₂₄) to that observed in humans receiving 8 mg kg⁻¹ of 666 667 intravenous daptomycin⁶⁵]. The above antibiotic dosing protocol was followed for 7 days. Faecal samples were collected at specific time points throughout the experiment to 668 669 determine VREfm gut colonisation and for downstream rifamycin and daptomycin resistance 670 analysis. Faecal samples were resuspended in PBS to a normalised concentration (100 mg ml⁻ 671 ¹). Serial dilutions were performed, and samples were plated onto Brilliance VRE agar (Oxiod) for VREfm CFU enumeration. 672

For rifamycin and daptomycin analysis, VREfm colonies (n=50 per mouse) from the Brilliance
VRE agar plates were replica plated onto BHIA with and without rifampicin 20 mg mL⁻¹ to

675 determine the proportion of rifampicin-resistant VREfm in each mouse. All colonies (n=50 per 676 mouse) were then screened for daptomycin resistance using a daptomycin screen. Of which, 677 a single colony was resuspended in PBS, then diluted 1/100 into CAMHBT containing 50 mg L⁻ ¹ Ca²⁺, and 1/100 in MH containing 50 mg L⁻¹ Ca²⁺, and 8 mg L⁻¹ daptomycin. All suspected 678 679 daptomycin-resistant colonies were confirmed using a daptomycin BMD MIC as before. 680 To determine which mutations were present in the rifamycin-resistant isolates, a random 681 selection of 300 colonies, 150 from rifaximin treated mice and 150 from rifampicin treated 682 mice, were sampled for WGS as described above.

683 Analysis of VREfm isolates from patients receiving rifaximin.

684 To examine the potential association of rifaximin use in humans and the presence of 685 daptomycin-resistant VREfm strains, we analysed VREfm collected between 2018 and 2021 686 from a single hospital institution in Melbourne. These isolates underwent WGS and daptomycin and rifampicin susceptibility testing as before. Isolates were stratified according 687 688 to whether the patient received rifaximin within 1 month of VREfm isolation or remained 689 rifaximin free prior to isolate collection. The majority (80%) of isolates were routine screening 690 samples. This included 50 VREfm isolates from patients receiving or previously receiving 691 rifaximin at time of isolation, which were randomly matched to 50 VREfm isolates from 692 patients not receiving rifaximin administration. All isolates were collected within the same 693 time frame. The VREfm isolates were visualised in a maximum-likelihood phylogenetic tree as before, using a core-SNP alignment of 12,430 sites. Isolate MLST was defined with the mlst 694 695 tool mutations determined and in RpoB were using Snippy 696 (https://github.com/tseemann/snippy) (v4.4.5) as described.

697 **Data visualisation and statistics**

- 698 All figures were generated in R (v4.0.3, <u>https://www.r-project.org/</u>) using tidyverse (v.1.3.1),
- 699 patchwork (v.1.1.1), and ggnewscale (v.0.4.5). Statistical analyses were performed using R
- 700 (v4.0.3, <u>https://www.r-project.org/</u>) and GraphPad Prism (v9.3.1) software packages. Specific
- 701 tests are given together with each result in the text.
- 702 Ethics approval
- 703 Ethical approval for analysis of patient data was received from the University of Melbourne
- 704 Human Research Ethics Committee (study number 1954615.3).
- 705 Competing Interests
- 706 The authors declare no competing interests.

707 Acknowledgements

- 708 This work was supported by the National Health and Medical Research Council (NHMRC) of
- Australia (GNT1185213 and GNT1160745). BPH is supported by an NHMRC Investigator Grant
- 710 (GNT1196103). JCK is supported by an NHMRC Early Career Fellowship (GNT1142613). AMT
- and NLS are supported by an Australian Government Research Training Program scholarship.
- The Controlling Superbugs study was supported by the Melbourne Genomics Health Alliance
- 713 (funded by the State Government of Victoria, Department of Health and Human Services, and
- the 10 member organizations).

715 Author Contributions

- 716 GPC, BPH, and CLG conceived and planned the experiments. AMT, LL, IRM, DLI, SD, and GPC
- 717 performed the planned experiments. JCK provided access to necessary patient metadata and
- clinical VREfm isolates that were used in the study. JYHL, NLS, TPS, and JCK provided critical
- 719 clinical or bioinformatic insights for the study. AMT, CLG, and GPC co-wrote the manuscript
- 720 with critical feedback and input from all authors.
- 721 Corresponding Authors

722 Correspondence to Glen Carter or Benjamin Howden.

723 Data Availability

- 724 The data presented in the study are deposited under Bioprojects PRJNA565795,
- 725 PRJNA433676, PRJNA856406, and PRJNA856406.

726

727 References

- 1. Murray, C. J. et al. Global burden of bacterial antimicrobial resistance in 2019: a
- 729 systematic analysis. *The Lancet* **399**, 629–655 (2022).
- 730 2. Bylicka-Szczepanowska, E. & Korzeniewski, K. Asymptomatic Malaria Infections in the
- 731 Time of COVID-19 Pandemic: Experience from the Central African Republic. *Int. J. Environ.*
- 732 *Res. Public. Health* **19**, 3544 (2022).
- 733 3. Global HIV & AIDS statistics Fact sheet. https://www.unaids.org/en/resources/fact-
- 734 sheet.
- 4. GBD 2019 Collaborators. Global mortality from dementia: Application of a new method
- and results from the Global Burden of Disease Study 2019. *Alzheimers Dement. N. Y. N* 7,

737 e12200 (2021).

- 738 5. Arias, C. A. & Murray, B. E. The rise of the *Enterococcus*: beyond vancomycin resistance.
 739 *Nat. Rev. Microbiol.* **10**, 266–278 (2012).
- 740 6. Top, J., Willems, R. & Bonten, M. Emergence of CC17 Enterococcus faecium: from
- 741 commensal to hospital-adapted pathogen. *FEMS Immunol. Med. Microbiol.* 52, 297–308
 742 (2008).
- 743 7. Arthur, M. & Courvalin, P. Genetics and mechanisms of glycopeptide resistance in

enterococci. Antimicrob. Agents Chemother. **37**, 1563–1571 (1993).

- 745 8. Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO
- 746 priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect. Dis.* **18**, 318–

747 327 (2018).

- 9. Montero, C. I., Stock, F. & Murray, P. R. Mechanisms of Resistance to Daptomycin in
- 749 Enterococcus faecium. Antimicrob. Agents Chemother. (2008) doi:10.1128/AAC.00774-07.

- 750 10. Greene, M. H. et al. Risk Factors and Outcomes Associated With Acquisition of
- 751 Daptomycin and Linezolid–Nonsusceptible Vancomycin-Resistant *Enterococcus*. Open
- 752 Forum Infect. Dis. 5, ofy185 (2018).
- 11. Egli, A. et al. Association of daptomycin use with resistance development in
- 754 *Enterococcus faecium* bacteraemia—a 7-year individual and population-based analysis.
- 755 *Clin. Microbiol. Infect.* **23**, 118.e1-118.e7 (2017).
- 756 12. Diaz, L. *et al.* Whole-Genome Analyses of *Enterococcus faecium* Isolates with Diverse
 757 Daptomycin MICs. *Antimicrob. Agents Chemother.* (2014).
- 758 13. Lellek, H. et al. Emergence of daptomycin non-susceptibility in colonizing
- vancomycin-resistant *Enterococcus faecium* isolates during daptomycin therapy. *Int. J.*
- 760 *Med. Microbiol.* **305**, 902–909 (2015).
- 761 14. Kelesidis, T., Tewhey, R. & Humphries, R. M. Evolution of high-level daptomycin
- 762 resistance in *Enterococcus faecium* during daptomycin therapy is associated with limited
- 763 mutations in the bacterial genome. J. Antimicrob. Chemother. 68, 1926–1928 (2013).
- 15. Werth, B. J. et al. Defining Daptomycin Resistance Prevention Exposures in
- 765 Vancomycin-Resistant Enterococcus faecium and E. faecalis. Antimicrob. Agents
- 766 *Chemother.* **58**, 5253–5261 (2014).
- 767 16. Turner, A. M., Lee, J. Y. H., Gorrie, C. L., Howden, B. P. & Carter, G. P. Genomic
- 768 Insights Into Last-Line Antimicrobial Resistance in Multidrug-Resistant *Staphylococcus* and
- 769 Vancomycin-Resistant *Enterococcus*. Front. Microbiol. **12**, (2021).
- 17. Li, L. et al. Daptomycin Resistance Occurs Predominantly in vanA-Type Vancomycin-
- 771 Resistant *Enterococcus faecium* in Australasia and Is Associated With Heterogeneous and
- 772 Novel Mutations. *Front. Microbiol.* **12**, 749935 (2021).

18. Bass, N. M. et al. Rifaximin Treatment in Hepatic Encephalopathy. N. Engl. J. Med.

362, 1071–1081 (2010).

775 19. Shayto, R. H., Abou Mrad, R. & Sharara, A. I. Use of rifaximin in gastrointestinal and

776 liver diseases. *World J. Gastroenterol.* **22**, 6638–6651 (2016).

- 20. Sherry, N. L. et al. Pilot study of a combined genomic and epidemiologic surveillance
- 778 program for hospital-acquired multidrug-resistant pathogens across multiple hospital

networks in Australia. Infect. Control Hosp. Epidemiol. 42, 573–581 (2021).

780 21. Gorrie, C. L. et al. Key parameters for genomics-based real-time detection and

- 781 tracking of multidrug-resistant bacteria: a systematic analysis. Lancet Microbe 2, e575–
- 782 e583 (2021).

783 22. Miller, W. R., Bayer, A. S. & Arias, C. A. Mechanism of Action and Resistance to

784 Daptomycin in *Staphylococcus aureus* and Enterococci. *Cold Spring Harb. Perspect. Med.*

6, a026997 (2016).

786 23. Prater, A. G. et al. Environment Shapes the Accessible Daptomycin Resistance

787 Mechanisms in *Enterococcus faecium*. *Antimicrob*. *Agents Chemother*. **63**, e00790-19.

788 24. Bæk, K. T. et al. Stepwise Decrease in Daptomycin Susceptibility in Clinical

789 Staphylococcus aureus Isolates Associated with an Initial Mutation in rpoB and a

790 Compensatory Inactivation of the clpX Gene. Antimicrob. Agents Chemother. (2015).

791 25. Cui, L. et al. An RpoB Mutation Confers Dual Heteroresistance to Daptomycin and

792 Vancomycin in *Staphylococcus aureus*. *Antimicrob*. *Agents Chemother*. (2010)

793 doi:10.1128/AAC.00437-10.

794 26. Goldstein, B. P. Resistance to rifampicin: a review. *J. Antibiot. (Tokyo)* 67, 625–630
795 (2014).

- 796 27. Rios, R. et al. Genomic Epidemiology of Vancomycin-Resistant Enterococcus faecium
- 797 (VREfm) in Latin America: Revisiting The Global VRE Population Structure. Sci. Rep. 10,

798 5636 (2020).

- 799 28. Duchêne, S. et al. Genome-scale rates of evolutionary change in bacteria. Microb.
- 800 *Genomics* **2**, e000094 (2016).
- 801 29. Lebreton, F. et al. Emergence of Epidemic Multidrug-Resistant Enterococcus faecium
- from Animal and Commensal Strains. *mBio* **4**, e00534-13.
- 803 30. Raven, K. E. et al. A decade of genomic history for healthcare-associated
- 804 Enterococcus faecium in the United Kingdom and Ireland. Genome Res. 26, 1388–1396
- 805 (2016).
- 806 31. Goel, A., Rahim, U., Nguyen, L. H., Stave, C. & Nguyen, M. H. Systematic review with
- 807 meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis. *Aliment*.
- 808 *Pharmacol. Ther.* **46**, 1029–1036 (2017).
- 809 32. Lee, R. A. et al. Daptomycin-Resistant Enterococcus Bacteremia Is Associated With
- 810 Prior Daptomycin Use and Increased Mortality After Liver Transplantation. *Open Forum*
- 811 Infect. Dis. 9, ofab659 (2022).
- 812 33. Morley, V. J. et al. An adjunctive therapy administered with an antibiotic prevents
- enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen. *eLife* 9,
 e58147 (2020).
- 815 34. Bender, J. K. et al. Update on prevalence and mechanisms of resistance to linezolid,
- 816 tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature.
- 817 Drug Resist. Updat. 40, 25–39 (2018).

- 818 35. Tran, T. T. et al. Whole-Genome Analysis of a Daptomycin-Susceptible Enterococcus
- 819 *faecium* Strain and Its Daptomycin-Resistant Variant Arising during Therapy. *Antimicrob*.
- 820 Agents Chemother. **57**, 261–268 (2013).
- 821 36. Zaw, M. T., Emran, N. A. & Lin, Z. Mutations inside rifampicin-resistance determining
- region of *rpoB* gene associated with rifampicin-resistance in *Mycobacterium tuberculosis*.
- 823 *J. Infect. Public Health* **11**, 605–610 (2018).
- 824 37. Lee, J. Y. H. et al. Global spread of three multidrug-resistant lineages of
- 825 Staphylococcus epidermidis. Nat. Microbiol. **3**, 1175–1185 (2018).
- 826 38. Guérillot, R. et al. Convergent Evolution Driven by Rifampin Exacerbates the Global
- 827 Burden of Drug-Resistant *Staphylococcus aureus*. *mSphere* **3**, e00550-17.
- 828 39. Albarillo, F. S., Medina, R. E., Joyce, C. S., Darji, H. & Santarossa, M. Daptomycin-
- resistant VRE infections: a descriptive analysis at a single academic centre. *Infect. Dis.* 53,
 393–395 (2021).
- 40. Teillant, A., Gandra, S., Barter, D., Morgan, D. J. & Laxminarayan, R. Potential burden
- of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the
- USA: a literature review and modelling study. *Lancet Infect. Dis.* **15**, 1429–1437 (2015).
- 834 41. Berríos-Torres, S. I. et al. Activity of Commonly Used Antimicrobial Prophylaxis
- 835 Regimens against Pathogens Causing Coronary Artery Bypass Graft and Arthroplasty
- 836 Surgical Site Infections in the United States, 2006–2009. *Infect. Control Hosp. Epidemiol.*
- **35**, 231–239 (2014).
- B38 42. Dyar, O. J., Huttner, B., Schouten, J. & Pulcini, C. What is antimicrobial stewardship? *Clin. Microbiol. Infect.* 23, 793–798 (2017).

- 43. Lee, R. S. *et al.* The changing landscape of vancomycin-resistant *Enterococcus*
- 841 *faecium* in Australia: a population-level genomic study. J. Antimicrob. Chemother. **73**,
- 842 3268–3278 (2018).
- 843 44. Snyder, E. E. *et al.* PATRIC: The VBI PathoSystems Resource Integration Center.
- 844 *Nucleic Acids Res.* **35**, D401–D406 (2007).
- 845 45. Wood, D. E., Lu, J. & Langmead, B. Improved metagenomic analysis with Kraken 2.
 846 *Genome Biol.* 20, 257 (2019).
- 847 46. Humphries, R. M. The New, New Daptomycin Breakpoint for *Enterococcus* spp. J.
- 848 *Clin. Microbiol.* **57**, e00600-19.
- 849 47. Lam, M. M. et al. Comparative analysis of the complete genome of an epidemic
- 850 hospital sequence type 203 clone of vancomycin-resistant *Enterococcus faecium*. BMC
- 851 *Genomics* **14**, 595 (2013).
- 852 48. Bankevich, A. et al. SPAdes: A New Genome Assembly Algorithm and Its Applications

to Single-Cell Sequencing. J. Comput. Biol. **19**, 455–477 (2012).

- 854 49. Schliep, K. P. phangorn: phylogenetic analysis in R. *Bioinformatics* 27, 592–593
 855 (2011).
- 856 50. Paradis, E. & Schliep, K. ape 5.0: an environment for modern phylogenetics and
 857 evolutionary analyses in R. *Bioinformatics* 35, 526–528 (2019).
- 858 51. Yu, G., Smith, D. K., Zhu, H., Guan, Y. & Lam, T. T.-Y. ggtree: an r package for
- 859 visualization and annotation of phylogenetic trees with their covariates and other
- associated data. *Methods Ecol. Evol.* **8**, 28–36 (2017).
- 861 52. Crispell, J., Balaz, D. & Gordon, S. V. HomoplasyFinder: a simple tool to identify
- homoplasies on a phylogeny. *Microb. Genomics* 5, e000245 (2019).

863	53.	Lees, J. A., Galardini, M., Bentley, S. D., Weiser, J. N. & Corander, J. pyseer: a			
864	con	nprehensive tool for microbial pangenome-wide association studies. Bioinformatics			
865	34 , 4310–4312 (2018).				
866	54.	de Been, M. et al. Core Genome Multilocus Sequence Typing Scheme for High-			
867	Res	olution Typing of Enterococcus faecium. J. Clin. Microbiol. 53, 3788–3797 (2015).			
868	55.	Croucher, N. J. et al. Rapid phylogenetic analysis of large samples of recombinant			
869	bac	terial whole genome sequences using Gubbins. Nucleic Acids Res. 43, e15 (2015).			
870	56.	Nguyen, LT., Schmidt, H. A., von Haeseler, A. & Minh, B. Q. IQ-TREE: A Fast and			
871	Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies. Mol. Biol.				
872	Evo	<i>I.</i> 32 , 268–274 (2015).			
873	57.	Rambaut, A., Lam, T. T., Max Carvalho, L. & Pybus, O. G. Exploring the temporal			
874	structure of heterochronous sequences using TempEst (formerly Path-O-Gen). Virus Evol.				
875	2 , v	ew007 (2016).			
876	58.	Suchard, M. A. et al. Bayesian phylogenetic and phylodynamic data integration using			
877	BEA	AST 1.10. <i>Virus Evol.</i> 4 , vey016 (2018).			
878	59.	Minin, V. N. & Suchard, M. A. Counting labeled transitions in continuous-time			
879	Ma	rkov models of evolution. J. Math. Biol. 56, 391–412 (2008).			
880	60.	Minin, V. N. & Suchard, M. A. Fast, accurate and simulation-free stochastic mapping.			
881	Phil	los. Trans. R. Soc. B Biol. Sci. 363 , 3985–3995 (2008).			
882	61.	Monk, I. R., Tree, J. J., Howden, B. P., Stinear, T. P. & Foster, T. J. Complete Bypass of			
883	Res	triction Systems for Major Staphylococcus aureus Lineages. mBio 6, e00308-15.			
884	62.	Zhang, Y., Werling, U. & Edelmann, W. Seamless Ligation Cloning Extract (SLiCE)			
885	Clo	ning Method. in DNA Cloning and Assembly Methods (eds. Valla, S. & Lale, R.) 235–244			
886	(Hu	mana Press, 2014). doi:10.1007/978-1-62703-764-8_16.			

- 887 63. Pidot, S. J. et al. Increasing tolerance of hospital Enterococcus faecium to handwash
- 888 alcohols. *Sci. Transl. Med.* **10**, eaar6115 (2018).
- 889 64. Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals
- and human. J. Basic Clin. Pharm. 7, 27–31 (2016).
- 891 65. Heine, H. S., Bassett, J., Miller, L., Purcell, B. K. & Byrne, W. R. Efficacy of Daptomycin
- against *Bacillus anthracis* in a Murine Model of Anthrax Spore Inhalation. *Antimicrob*.
- 893 Agents Chemother. **54**, 4471–4473 (2010).
- 894
- 895



896

897 Figure 1. A. Manhattan plot of 10,530 variants, displayed by position on the reference 898 genome and significance association with daptomycin resistance (univariate analysis using a 899 linear mixed model). The dashed line shows the Bonferroni-corrected significance threshold. 900 B. Percentage of daptomycin-resistant strains for each mutation within RpoB. The mutations 901 within the rifampicin resistance determining region (RRDR) are shown in bold. Mutations 902 coloured in red were associated with daptomycin resistance. The total number of strains 903 containing each mutation is shown above each bar. C. Maximum-likelihood core-SNP-based 904 phylogeny of clinical VREfm (n=1000) inferred from 6,574 SNPs, demonstrating the presence 905 of RpoB mutations in daptomycin-resistant isolates. Overlaid are the results of in silico multi-906 locus sequence type (MLST), daptomycin phenotypic testing, and mutations associated with 907 daptomycin resistance in RpoB. In the first circle, ST is not shown for uncommon STs ($n \le 5$). 908 The scale bar indicates number of nucleotide substitutions per site (top), with an 909 approximation of SNP distance (in parentheses). D. Rifampicin susceptibility testing results 910 for the WT, isogenic rpoB and liaRS isogenic mutants and complement strains (designated 911 with -C) (n=3). E. Daptomycin susceptibility testing results for the WT, rpoB and liaRS isogenic 912 mutants and complement strains (designated with -C) (n=3). The median MIC for each strain 913 is shown.





Figure 2. A. Map of 4,476 VREfm genomes included in this study. Circle size corresponds to total number of genomes (binned into categories), and colour corresponds to region of isolation. Country coordinates used are the country centroid position. Map was generated in R using ggplot2. **B.** The frequency of various RpoB mutations within the rifampicin resistance determining region (RRDR) in 4,476 VREfm genomes, sampled from 43 MLSTs. Bars are coloured by the number of isolates from each region of isolation containing the mutation. The identified daptomycin resistance associated mutations are coloured in red.



923 Figure 3. A. Maximum-likelihood, core-SNP-based phylogeny for 4,476 VREfm inferred from 924 9,277 core-genome SNPs, demonstrating the presence of the S491F RpoB mutation in 925 international VREfm. Overlaid is the region of isolation for each strain and the presence of the S491F mutation. The coloured branches indicate the three VREfm clusters identified with 926 927 cgMLST used as input for Bayesian evolutionary analyses. The scale bar indicates number of 928 nucleotide substitutions per site (top), with an approximation of SNP distance (in 929 parentheses). B. Bayesian phylodynamic analyses showing the maximum-clade credibility 930 (MCC) trees of the three VREfm clusters with the timing of emergence for each lineage. 931 Cluster 1 (n=219) was inferred from a core alignment of 1,869,554 bp containing 329 SNP 932 sites; Cluster 2 (n=85) was inferred from an alignment of 1,524,024 bp containing 541 SNP 933 sites; and Cluster 3 (n=68) was inferred from an alignment of 1,860,780 bp containing 764 934 SNP sites. The time in years is given on the x axis. The presence of the S491F RpoB trait for 935 each isolate is shown in purple. Overlaid onto the MCC trees is the first instance of FDA 936 approval for rifaximin (2004) and for hepatic encephalopathy (HE) (2010). C. Violin plots for 937 the most recent common ancestor (MCRA) for each cluster, representing when the RpoB 938 S491F mutation first emerged, with 95% HPD intervals. Overlaid onto violin plots is the FDA 939 approval date for rifaximin (2004).



940

941 Figure 4. A. Timeline of the mouse experiment. VREfm-colonised mice (n=5 for vehicle, n=10 942 for rifampicin, n=10 for rifaximin, n=10 for daptomycin) received a human-equivalent dose of 943 vehicle, rifampicin, or rifaximin (twice per day for rifaximin) for 7 days by oral gavage or 944 subcutaneous injection with daptomycin for 7 days. CRO=ceftriaxone; DAP=daptomycin; 945 RIFAX=rifaximin; RIF=rifampicin. Figure to scale. B. Percentage of total mice with rifampicin-946 resistant VREfm strains C. or daptomycin-resistant VREfm strains after 7 days of antibiotic 947 treatment. D. Percentage of VREfm from each mouse (n=50 colonies per mouse) that were 948 resistant to rifampicin E. or daptomycin after 7 days of antibiotic treatment. Points represent 949 an individual mouse. Percentage was calculated from rifampicin or daptomycin MIC values 950 (either resistant or susceptible) from 50 VREfm colonies isolated from each mouse. Boxes represent the median and interquartile range for each group. F. Overview of the RpoB 951 952 mutations identified in the rifampicin-resistant colonies. Each point represents a single 953 colony. Isolates are separated by each RpoB mutation and grouped into either daptomycin-954 susceptible or daptomycin-resistant. The RpoB mutations coloured in red had an association 955 with daptomycin resistance. n values represent the number of isolates containing each mutation for rifaximin and rifampicin, respectively. *P < 0.05, **P < 0.01, ***P < 0.001, 956 957 ****P<0.0001; unpaired t-test (vehicle versus rifampicin or vehicle versus rifaximin and 958 rifampicin verses daptomycin or rifaximin verses daptomycin).



Figure 5. A. Maximum-likelihood core-SNP-based phylogeny of clinical VREfm (n=100) 960 inferred from 12,430 SNPs. Overlaid is the results of *in silico* MLST, rifaximin treatment group, 961 962 rifampicin phenotypic testing, daptomycin phenotypic testing, and mutations in RpoB. 963 Mutations associated with daptomycin resistance are bolded. The scale bar indicates number 964 of nucleotide substitutions per site (top), with an approximation of SNP distance (in 965 parentheses). B. Rifampicin susceptibility data for clinical VREfm (n=50 per group). Red bars 966 represent percent of rifampicin-resistant isolates. A Fisher's exact test comparing the percentage of rifampicin resistance in the control versus rifaximin, P < 0.0001. C. Daptomycin 967 968 susceptibility data for clinical VREfm (n=50 per group). Red bars represent percent of 969 daptomycin-resistant isolates. A Fisher's exact test comparing the percentage of daptomycin 970 resistance in the control versus rifaximin, P < 0.0001.